Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNC210

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Apeiron Investment Group

            Deal Size: $22.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 02, 2020

            Details:

            The financing guarantees the Company's substantiated funding to advance Phase 2 clinical trials for the treatment of PTSD and other anxiety and stress-related disorders for its lead compound, BNC210.